Komori
Alfresa Holdings (2784) · InitiativeFirst stated

Joint research with Hiroshima University Hospital on diagnostic technologies for emerging infectious diseases

First written in 2026-05-15. . Latest entry: 2026-05-15.

1entries
1years
1from disclosures
Share on X
How it moved
Same theme, other companies

This thread is not in a theme yet. When the same subject shows up in other companies' filings, you can compare them here.

Full recordFilings, disclosures and news, newest first
  1. 2026-05-15First statedOther Disclosures

    「Research scope: In addition to developing a rapid test kit based on immunochromatography to detect SFTS virus antigens and conducting performance evaluations and clinical studies with a view to practical use in clinical settings, the parties will conduct basic research on relevant viruses and other pathogens and promote the development of testing methods based on the findings, with the aim of establishing diagnostic technologies and systems capable of addressing future emerging infectious diseases.」

    The establishment of a clinical emerging infectious disease joint research program at Hiroshima University Hospital was newly disclosed, launching a project to develop a rapid SFTS test kit and establish diagnostic technologies and systems for future emerging infectious diseases.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Alfresa Holdings yet. It last moved in the Other Disclosures of 2026-05-15: "First stated".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.